Neither molecular testing nor PD-L1 assessment was performed in 22% of patients with non-squamous NSCLC, 29% of patients with NOS patients, and 49% of patients with squamous NSCLC (Table 2). This evidence concerns the gene CD274 and non-small cell lung carcinoma.